🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

126 results for “pembrolizumab” Clear

  1. PEMBROLIZUMAB

    Pari Pharma GmbH

    Kaposi's sarcoma

    phase 2 small molecule active

    1 trial

  2. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  3. PEMBROLIZUMAB, ATEZOLIZUMAB, NIVOLUMAB, CEMIPLIMAB

    Fondazione Telethon ETS

    Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  4. PEMBROLIZUMAB, DARAXONRASIB (RMC-6236), CARBOPLATIN, DARAXONRASIB (RMC-6236), PEMETREXED, CISPLATIN, RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  5. PEMBROLIZUMAB, OLAPARIB, OLAPARIB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

  6. PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ENCORAFENIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    MSI-H/dMMR metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  7. PEMBROLIZUMAB, PM54

    Pharma Mar S.A.

    Advanced malignancies

    phase 2 small molecule active

    1 trial

  8. PEMETREXED DISODIUM, PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, GEN1055 DP, CISPLATIN, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  9. Pembrolizumab

    Bicara Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  10. Pembrolizumab

    United Therapeutics Europe Ltd

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  11. Pembrolizumab

    United Therapeutics Europe Ltd

    Metastatic Small Intestinal Adenocarcinoma

    phase 2 mab active

    1 trial

  12. Pembrolizumab

    United Therapeutics Europe Ltd

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  13. Pembrolizumab

    United Therapeutics Europe Ltd

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  14. Pembrolizumab

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 2 mab terminated

    1 trial

  15. Pembrolizumab

    Syndax Pharmaceuticals Inc

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  16. Pembrolizumab

    Syndax Pharmaceuticals Inc

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  17. Pembrolizumab

    Inhibrx Biosciences

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Pembrolizumab

    IO Biotech

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. Pembrolizumab

    Karyopharm Therapeutics

    Advanced Urothelial Carcinoma

    phase 2 mab terminated

    1 trial

  20. Pembrolizumab

    ALX ONCOLOGY HOLDINGS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  21. Pembrolizumab

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  22. Pembrolizumab (200mg IV for 30 minutes

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  23. Pembrolizumab (KEYTRUDA®) and PDS0101

    PDS Biotechnology Corp

    Metastatic Head and Neck Cancer

    phase 2 other completed

    1 trial

  24. Pembrolizumab 200 mg IV infusion

    China SXT Pharmaceuticals

    Stage IIIB(N2) Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources